Maximum quantity allowed is 999
“Non-Fucosyl G2 N-Glycan” Expected as a High-Functional Glycoform for Therapeutic Antibody
G2-peptide (1) is practically available as a structure-defined glycan donor in the “enzymatic N-glycan remodeling technology” to convert glycosylation of glycoprotein from heterogeneous non-core fucosylated biantennary N-glycans to homogeneous G2 N-glycan. It has been reported that antibodies possessing "non-fucosyl G2 glycoform” show functional improvements in physiological phenomena such as antibody-dependent cellular cytotoxicity (ADCC) activity, complement-dependent cytotoxicity (CDC) activity, and anti-inflammatory effect by the US National Institutes of Health (NIH) and the JP National Institute of Health Sciences (NIHS) and other institutes. Thus, "non-fucosyl G2 N-glycan” has been an attractive glycan structure in biopharmaceutical fields in recent years.1-4) Please contact us for mass production of 1. In addition, G2 glycan (2), G2 2AB (500pmol/vial) (3) and nonasaccharide-β-pNP (4) are also available as reagents for comparative analyses, enzyme substrates and so on.
References
- 1) Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
- 2) Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered FcγReceptor IIIa-Immobilized Column
- 3) Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa
- 4) Anti-inflammatory activity of galactosylated, nonfucosylated intravenous immunoglobulin
Related Compounds
The prices are subject to change without notice. Please confirm the newest price by our online catalog before placing an order.
In addition, sales products changes with areas. Please understand that a product is not available when the product details page is not displayed.